Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Gastrointest Endosc. 2011 Apr;73(4):673-81. doi: 10.1016/j.gie.2010.11.014. Epub 2011 Jan 26.
Fully covered esophageal self-expandable metal stents (FCSEMSs) are thought to induce less mucosal hyperplasia and are potentially removable. They may constitute an attractive alternative for the treatment of benign esophageal diseases.
To evaluate the efficacy and safety of FCSEMSs in the treatment of benign esophageal diseases.
Patients referred for management of benign esophageal disease underwent placement of an FCSEMS and were entered into a prospective database and analyzed retrospectively for clinical response, efficacy, and morbidity.
Two tertiary care centers with long-standing experience in the management of benign esophageal strictures.
Between January 2006 and September 2007, 35 patients (mean age 61 years, range 20-85 years) underwent FCSEMS placement for benign esophageal diseases at 2 tertiary academic medical centers. There were 19 patients with benign esophageal strictures and 16 patients with leaks/perforations.
Temporary placement of FCSEMS until stricture resolution.
Clinical response, efficacy, and morbidity.
Indications for stent placement were esophageal leak/fistulae (n = 12), refractory benign strictures (n = 10), anastomotic strictures (n = 7), perforations (n = 4), and radiation-induced strictures (n = 2). Immediate complications were chest pain (2 patients), stent migration (2 patients), dysphagia (1 patient), respiratory compromise (1 patient), and arrhythmia (1 patient). Long-term complications included recurrent dysphagia (6 patients), aspiration pneumonia (2 patients), globus sensation (2 patients), abdominal pain (2 patients), and fever (1 patient). Stent migration was observed in 12 patients (34%). After placement, dysphagia scores at 1 month improved significantly from 3.1 ± 1.0 to 1.2 ± 1.3 (P < .0001). A total of 11 of 35 patients (31%) were treated successfully. Specifically, 21% of patients with refractory strictures and 44% of patients with leaks/fistulae had successful long-term outcomes without any need for reinterventions. All stents were retrieved successfully, except for 1 stent, which fractured and was retrieved in 2 pieces without any complications.
Use of FCSEMSs for benign esophageal conditions was associated with frequent stent migration and long-term improvement in only one third of patients. Further investigation is required before recommending FCSEMS placement to treat benign diseases of the esophagus and to further characterize the subgroup that might benefit from these interventions.
全覆膜食管自膨式金属支架(FCSEMS)被认为引起的黏膜增生较少,且具有潜在的可移除性。对于良性食管疾病的治疗,它们可能是一种有吸引力的替代方法。
评估 FCSEMS 在治疗良性食管疾病中的疗效和安全性。
因良性食管疾病而接受治疗的患者接受 FCSEMS 放置,并被纳入一个前瞻性数据库,对其临床反应、疗效和发病率进行回顾性分析。
两个拥有长期良性食管狭窄管理经验的三级保健中心。
2006 年 1 月至 2007 年 9 月,在 2 个三级学术医疗中心,35 例(平均年龄 61 岁,范围 20-85 岁)因良性食管疾病接受 FCSEMS 放置。其中 19 例为良性食管狭窄,16 例为食管漏/穿孔。
FCSEMS 临时放置直至狭窄缓解。
临床反应、疗效和发病率。
支架置入的指征为食管漏/瘘(n=12)、难治性良性狭窄(n=10)、吻合口狭窄(n=7)、穿孔(n=4)和放射性狭窄(n=2)。即刻并发症为胸痛(2 例)、支架移位(2 例)、吞咽困难(1 例)、呼吸窘迫(1 例)和心律失常(1 例)。长期并发症包括复发性吞咽困难(6 例)、吸入性肺炎(2 例)、咽部异物感(2 例)、腹痛(2 例)和发热(1 例)。12 例(34%)患者发生支架移位。支架置入后 1 个月,吞咽困难评分从 3.1±1.0 显著改善至 1.2±1.3(P<0.0001)。35 例患者中共有 11 例(31%)得到成功治疗。具体而言,21%的难治性狭窄患者和 44%的食管漏/穿孔患者无需进一步干预即可获得长期成功结局。所有支架均成功取出,除 1 枚支架断裂并以 2 段形式取出,无任何并发症。
FCSEMS 用于良性食管疾病时支架频繁移位,只有三分之一的患者长期预后得到改善。在推荐 FCSEMS 放置治疗食管良性疾病并进一步明确可能从这些干预中获益的亚组之前,需要进一步研究。